Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Mark Edlund is a member of the firm’s Corporate Practice Group and represents clients in corporate transactions, including mergers and acquisitions and domestic and cross-border capital markets transactions. He also advises clients on general corporate matters, including SEC reporting and compliance and corporate governance.

  • Represented the underwriters in the $172 million U.S. follow-on offering of ordinary shares of an Israeli biopharmaceutical company focused on uro-oncology.
  • Represented the underwriters in the $40 million follow-on offering of shares of common stock of a pharmaceutical company focused on the treatment of inflammatory and fibrotic diseases.
  • Represented the sales agent in establishing a U.S. “at-the-market” offering program for shares of common stock of a Canadian animal health company.
  • Represented the underwriters in the $20 million U.S. follow-on offering of American Depositary Shares of an Israeli biopharmaceutical company focused on the treatment of gastrointestinal diseases and cancers.
  • Represented the sales agent in establishing an “at-the-market” offering program for shares of common stock of a biopharmaceutical company focused on hemato-oncology.
  • Represented a biopharmaceutical company in activating its “at-the-market” offering program.